Spotlight On European Penny Stocks For October 2026

The European market has recently experienced a tug-of-war between signs of improving growth and concerns over potential tightening monetary policies due to high energy prices. In this context, penny stocks—often smaller or newer companies—remain an intriguing investment area despite being a somewhat outdated term. These stocks can offer unique growth opportunities when backed by strong financials, standing out as promising candidates for investors seeking under-the-radar companies with long-term potential.

Let's review some notable picks from our screened stocks.

Piquadro (BIT:PQ)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Piquadro S.p.A. designs, produces, and markets leather goods and accessories in Italy, Europe, and internationally with a market cap of €116.38 million.

Operations: The company's revenue is derived from its three main segments: Lancel (€74.45 million), Piquadro (€73.22 million), and The Bridge (€36.65 million).

Market Cap: €116.38M

Piquadro S.p.A. shows a mixed financial profile, with its short-term assets exceeding both short and long-term liabilities, indicating strong liquidity. The company has demonstrated consistent earnings growth over the past five years at 40.9% annually, although recent growth slowed to 11.2%. Its debt management is commendable, with more cash than total debt and interest payments well-covered by EBIT. Despite a low return on equity of 17.2%, Piquadro's price-to-earnings ratio of 9x suggests it may be undervalued compared to the broader Italian market. However, an inexperienced board and an unstable dividend track record could pose challenges for investors seeking stability in penny stocks.

• Dive into the specifics of Piquadro here with our thorough balance sheet health report.
• Learn about Piquadro's future growth trajectory here.

Dataproces Group (CPSE:DATA)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Dataproces Group A/S, along with its subsidiaries, develops and delivers data analytics solutions in Denmark and has a market cap of DKK141.39 million.

Operations: The company generates revenue from its Computer Services segment, amounting to DKK57.93 million.

Market Cap: DKK141.39M

Dataproces Group A/S presents a mixed picture for investors in penny stocks, with its short-term assets comfortably covering both short and long-term liabilities, highlighting solid liquidity. The company's debt management is strong, with more cash than total debt and operating cash flow well exceeding its debt obligations. Despite these strengths, the company has faced negative earnings growth over the past year and a decline in profit margins from 13.7% to 9.3%. Recent strategic partnerships in Germany aim to bolster revenue streams but haven't altered current fiscal guidance. An inexperienced management team may present additional risks for potential investors.

• Click here and access our complete financial health analysis report to understand the dynamics of Dataproces Group.
• Examine Dataproces Group's past performance report to understand how it has performed in prior years.

Enzymatica (OM:ENZY)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Enzymatica AB (publ) is a life science company that develops and sells medical devices for infectious diseases, with a market cap of SEK421.15 million.

Operations: The company generates revenue of SEK51.93 million from its medical devices segment.

Market Cap: SEK421.15M

Enzymatica AB's financial health reflects a complex scenario for penny stock investors. The company is debt-free and maintains liquidity with short-term assets surpassing liabilities, yet it faces challenges with profitability as losses have increased by 1.9% annually over five years. Recent management changes, including the appointment of Bjarki Stefánsson as Chief Scientist, may bring strategic direction but the team remains relatively inexperienced. Despite reporting a slight reduction in net loss for the latest quarter compared to last year, Enzymatica continues to operate at a loss with less than one year of cash runway based on current free cash flow trends.

• Unlock comprehensive insights into our analysis of Enzymatica stock in this financial health report.
• Evaluate Enzymatica's historical performance by accessing our past performance report.

Turning Ideas Into Actions

• Click here to access our complete index of 298 European Penny Stocks.
• Interested In Other Possibilities? Rare earth metals are the new gold rush. Find out which 33 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com